Haemonetics Corporation (NYSE:HAE) is reporting second quarter financial results on Wednesday 4th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, HAE is expected to report 2Q21 income of $ 0.51 per share from revenue of $ 207.65 million.
For the full year, analysts anticipate top line of $ 869.34 million, while looking forward to income of $ 2.46 per share bottom line.
Previous Quarter Performance
Haemonetics Corporation unfold income for the first quarter of $ 0.46 per share, from the revenue of $ 195.58 million. The quarterly earnings declined 43.21 percent compared with the same quarter last year. Street analysts expected Haemonetics Corporation to report income of $ 0.41 per share on revenue of $ 198.27 million for the first quarter. The bottom line results beat street analysts by $ 0.05 or 12.20 percent, at the same time, top line results fell short of analysts by $ 2.69 million or 1.36 percent.
Stock Performance
Shares of Haemonetics Corporation traded up $ 0.50 or 0.49 percent on Tuesday, reaching $ 102.20 with volume of 259.30 thousand shares. Haemonetics Corporation has traded high as $ 103.26 and has cracked $ 101.30 on the downward trend
According to the previous trading day, closing price of $ 102.20, representing a 60.38 % increase from the 52 week low of $ 63.41 and a 19.76 % decrease over the 52 week high of $ 126.74.
The company has a market capital of $ 5.18 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Recent Analyst recommendations
- On 8th September 2020, maintained by Raymond James at Outperform rating, with $ 100.00 target price.
Conference Call
Haemonetics Corporation will be hosting a conference call at 8:00 AM eastern time on 4th November 2020, to discuss its 2Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.haemonetics.com
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through Japan, EMEA, North America Plasma, and All Other segments. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables, such as plasma collection containers and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
